MRNA
NasdaqModerna, Inc.
Basic Materials · Biological Products, (No Diagnostic Substances)
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$18.5B
2021
$19.3B
2022
$6.8B
2023
$3.2B
2024
$1.9B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$1.9B
Net Income$-2.8B
Gross Profit—
Oper Income$-3.1B
EPS (dil)$-7.26
Rev/sh$4.90
FCF/sh$-5.20
Book/sh$21.80
Gross M—
Oper M-158.1%
Profit M-145.2%
FCF M-106.2%
ROE-32.6%
ROA-22.9%
ROIC-47.2%
R&D/Rev161.1%
Rev Y/Y-39.9%
Rev 3Y CAGR-53.4%
EPS Y/Y21.8%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+1.3%
Current Ratio3.29
Quick Ratio3.22
Debt/Eq0.07
Int Coverage—
Net Debt$2.0B cash
Total Debt$590.0M
Cash & Eq$2.6B
Total Assets$12.3B
Oper CF$-1.9B
Capex$192.0M
Free CF$-2.1B
Buybacks$2.0M
Equity$8.7B
Liabilities$3.7B
Shs Outstand0.40B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |
| Gross Profit | — | — | — | — | — |
| Operating Income | $13.3B | $9.4B | $-4.2B | $-3.9B | $-3.1B |
| Net Income | $12.2B | $8.4B | $-4.7B | $-3.6B | $-2.8B |
| Diluted EPS | $28.29 | $20.12 | $-12.33 | $-9.28 | $-7.26 |
| Operating Cash Flow | $13.6B | $5.0B | $-3.1B | $-3.0B | $-1.9B |
| Free Cash Flow | $13.3B | $4.6B | $-3.8B | $-4.1B | $-2.1B |
COMMUNITY · $MRNA0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.